<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174523</url>
  </required_header>
  <id_info>
    <org_study_id>D1070003</org_study_id>
    <nct_id>NCT02174523</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects</brief_title>
  <official_title>Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuhui Central Hospital, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40
      mg lurasidone in healthy Chinese subjects.

      To evaluate the safety and tolerance after multiple oral administration of 40 mg lurasidone
      in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single oral administration of 40 mg study drug lurasidone or placebo after the over 350 kcal
      breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral
      administration of 40 mg study drug lurasidone or placebo, once daily between Day 4 and Day 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lurasidone Cmax</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>Maximum (peak) observed drug serum concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC 0-24</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC 0-τ</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC0-∞</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Tmax</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone λz</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone t1/2</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone MRT</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone CL/F</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLss/F</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Vz/F</measure>
    <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Vzss/F</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,</measure>
    <time_frame>Day 8/Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5</measure>
    <time_frame>Pre-dose (-0.5h) of Day4 and Day5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7</measure>
    <time_frame>Pre-dose (-0.5h) of Day6 and Day7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Cmax</measure>
    <time_frame>Day8</time_frame>
    <description>Maximum (peak) observed drug serum concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC 0-24</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC 0-τ</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC0-∞</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Tmax</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone λz</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone t1/2</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone MRT</measure>
    <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>40mg lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg lurasidone</intervention_name>
    <arm_group_label>40mg lurasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. After detailed explanations of study objectives, methods and procedures, anticipated
             efficacy, pharmacologic actions, risks and other relevant contents, subjects are aware
             of all relevant information related to this study and have signed the informed consent
             form voluntarily.

          2. Male subjects are 18≤ age &lt;40 years of age when signing the informed consent.

          3. Subjects with body weight of 50.0≤ and ≤80.0 kg and BMI (body mass index) of 19.0≤ and
             &lt;24.0 at screening examination.

          4. Subjects are able to comply with all requirements during this study period, receive
             various physical and laboratory examinations per study protocol, and report subjective
             symptoms.

        Exclusion Criteria:

          1. Based on the examination results during screening period, various physical and
             laboratory examinations performed 1 day before medication (Day -1) and before
             administration of study drug on the medication day, there are certain medical concerns
             on subject's health status in principal investigator's or study supervising
             physician's opinions (certain treatment or medical observation are deemed necessary).

          2. Subjects with past diabetic history.

          3. Subjects has an HbA1c level of &gt;6.2% at screening.

          4. Subjects with history of gastrointestinal operations (excluding appendectomy).

          5. Because of subjects' past medical history of cardiovascular diseases, liver diseases,
             renal diseases, endocrine disorders, digestive diseases, hematologic diseases,
             respiratory diseases, mental illness, neurological disorders (especially epilepsy and
             other convulsive disorders) and other diseases, subjects are unsuitable to participate
             in this study in the principal investigator's or study supervising physician's
             opinions.

          6. Subjects with past history of allergy to drugs.

          7. Subjects have consumed grapefruit or food containing grapefruit ingredients between 7
             days before medication (Day_-7) and before administration of study drug on the
             medication day (Day 1). Subjects have consumed food containing hypericum perforatum L.
             ingredients between 14 days before medication (Day_-14) and administration of study
             drug on the medication day (Day 1).

          8. Subjects have taken any drugs (including over-the-counter drugs) between 7 days before
             medication (Day_-7) and before administration of study drug on medication day.

          9. Regular drinker (criteria are mean daily consumption ≥2 bottles of 640 mL beers or
             Chinese liquor≥150 mL).

         10. Subjects are used to drink large amount (criteria are daily consumption&gt;1.8 L) of
             caffeine-containing beverages (e.g. coffee, black tea, green tea, coca cola or
             nutritional oral solution, etc).

         11. Subjects have history of drug abuse or positive urine drug tests.

         12. Subjects with positive immunologic test results.

         13. Average amount of daily smoking&gt;20 cigarettes.

         14. Subjects have taken other study drugs within 3 months (Day_-90~Day 1) before
             medication.

         15. Subjects received lurasidone orally before.

         16. Subjects have history of blood donations of 400 mL within 3 months (Day_-90~Day 1)
             before medication; 200 mL within 1 month (Day_-30~Day 1) before medication; or
             donation of blood components within 2 weeks (Day_-14~Day 1) before medication.

         17. Subjects have consumed alcohol-containing food between 3 days before medication 3
             (Day_-3) and before administration of study drug on medication day.

         18. Subjects can not tolerate venipuncture or have poor peripheral venous access.

         19. Subjects are unwilling to abstain from vigorous exercise from Day_-1 until discharge.

         20. Other subjects who are unsuitable to participate in this study in principal
             investigator's or study supervising physician's opinions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ChaoYing Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuhui Center Hospital, Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuhui Center Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>lurasidone</keyword>
  <keyword>multiple dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 27 subjects were screened at the clinical site after obtaining informed consent. A total 14 subjects were enrolled into the study and were randomized to lurasidone group (10) and placebo group (4). The data of informed consent from the first subject was 8th April 2014（and that from the last subject was 15th April 2014）.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>40mg Lurasidone</title>
          <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received lurasidone or placebo were included in the safety population. All subjects who received lurasidone and have evaluable PK data were included in the PK analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>40mg Lurasidone</title>
          <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="3.74"/>
                    <measurement group_id="B2" value="26.5" spread="5.07"/>
                    <measurement group_id="B3" value="27.4" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Cmax</title>
        <description>Maximum (peak) observed drug serum concentration.</description>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Cmax</title>
          <description>Maximum (peak) observed drug serum concentration.</description>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC 0-24</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC 0-24</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC 0-τ</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC 0-τ</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC0-∞</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC0-∞</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Tmax</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Tmax</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone λz</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone λz</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0360" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone t1/2</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone t1/2</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone MRT</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone MRT</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone CL/F</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone CL/F</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLss/F</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>CLss/F</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Vz/F</title>
        <time_frame>pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Vz/F</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6198" spread="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Vzss/F</title>
        <time_frame>Day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Vzss/F</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10618" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,</title>
        <time_frame>Day 8/Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,</title>
          <units>Ratios</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ratio of Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.75" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio of AUC0-∞</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="1.59" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio of AUC0-τ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.14" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio of Cτ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="2.37" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5</title>
        <time_frame>Pre-dose (-0.5h) of Day4 and Day5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5</title>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day4 Pre-dose (-0.5h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.277" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day5Pre-dose (-0.5h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7</title>
        <time_frame>Pre-dose (-0.5h) of Day6 and Day7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7</title>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day6 Pre-dose (-0.5h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7 Pre-dose (-0.5h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Cmax</title>
        <description>Maximum (peak) observed drug serum concentration.</description>
        <time_frame>Day8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Cmax</title>
          <description>Maximum (peak) observed drug serum concentration.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC 0-24</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC 0-24</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC 0-τ</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC 0-τ</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC0-∞</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC0-∞</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Tmax</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Tmax</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone λz</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone λz</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0199" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone t1/2</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone t1/2</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone MRT</title>
        <time_frame>Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8</time_frame>
        <population>All subjects with evaluable PK data were included in PK data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>40mg Lurasidone</title>
            <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone MRT</title>
          <population>All subjects with evaluable PK data were included in PK data analysis.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>40mg Lurasidone</title>
          <description>Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Hu Chaoying</name_or_title>
      <organization>Phase I Clinical Research Unit , Shanghai Xuihui Central Hospital</organization>
      <phone>021-54036058</phone>
      <email>cyhu@shxh-centerlab.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

